A Phase 1b Dose-Ranging Study to Assess the Safety, Pharmacokinetics and Initial Antiviral Efficacy of NVR 3-778 in Patients With HBeAg-Positive Chronic Hepatitis B Virus Infection
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2016
At a glance
- Drugs NVR 3778 (Primary) ; Antivirals
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Novira Therapeutics
- 15 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 17 Dec 2015 Planned end date changed from 1 Jan 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.
- 17 Dec 2015 Planned primary completion date changed from 1 Jan 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.